Page 149 - 南京医科大学自然版

第46卷第9期 林一响，孙 澳，张梅玲. FGFR信号通路在肿瘤中的作用机制与靶向治疗研究进展［J］.
2026年9月 南京医科大学学报（自然科学版），2026，46（9）：1412-1420，1436 ·1419 ·

4030-4046 cology targeting FGFRs：a systematic review on pre⁃clini⁃
［28］NISHIDA N，KUDO M. Genetic/epigenetic alteration and cal activity and clinical outcomes of pemigatinib［J］. Crit
tumor immune microenvironment in intrahepatic cholan⁃ Rev Oncol，2024，202：104464
giocarcinoma：transforming the immune microenviron⁃ ［40］VOGEL A，SAHAI V，HOLLEBECQUE A，et al. An open⁃
ment with molecular ⁃ targeted agents［J］. Liver Cancer， label study of pemigatinib in cholangiocarcinoma：final re⁃
2024，13（2）：136-149 sults from FIGHT ⁃ 202［J］. ESMO Open，2024，9（6）：
［29］HARDING J J，KHALIL D N，FABRIS L，et al. Rational 103488
development of combination therapies for biliary tract can⁃ ［41］PARISI A，DELAUNAY B，PINTERPE G，et al. Pemiga⁃
cers［J］. J Hepatol，2023，78（1）：217-228 tinib for patients with previously treated，locally advanced
［30］SMITH E A，BELOTE R L，CRUZ N M，et al. Receptor ty⁃ or metastatic cholangiocarcinoma harboring FGFR2 fu⁃
rosine kinase inhibition leads to regression of acral mela⁃ sions or rearrangements：a joint analysis of the French PE⁃
noma by targeting the tumor microenvironment［J］. J Exp MI⁃BIL and Italian PEMI⁃REAL cohort studies［J］. Eur J
Clin Cancer Res，2024，43（1）：317 Cancer，2024，200：113587
［31］SUZUKI H，IWAMOTO H，TANAKA T，et al. Fibroblast ［42］ILYAS S I，AFFO S，GOYAL L，et al. Cholangiocarcinoma⁃
growth factor inhibition by molecular⁃targeted agents miti⁃ novel biological insights and therapeutic strategies［J］.
gates immunosuppressive tissue microenvironment in he⁃ Nat Rev Clin Oncol，2023，20（7）：470-486
patocellular carcinoma［J］. Hepatol Int，2024，18（2）： ［43］LOTAN Y，RAMAN J D，KONETY B，et al. Urinary analy⁃
610-622 sis of FGFR3 and TERT gene mutations enhances perfor⁃
［32］VOGEL A，SEGATTO O，STENZINGER A，et al. FGFR2 mance of cxbladder tests and improves patient risk
inhibition in cholangiocarcinoma［J］. Annu Rev Med， stratification［J］. J Urol，2023，209（4）：762-772
2023，74：293-306 ［44］LORIOT Y，POWLES T，MORENO V，et al. Erdafitinib or
［33］CAO Z，YANG Y C，LIU S S，et al. FGFR2 fusions as⁃ erdafitinib plus cetrelimab for patients with metastatic
sessed by NGS，FISH，and immunohistochemistry in intra⁃ urothelial carcinoma and FGFR alterations：final results
hepatic cholangiocarcinoma［J］. J Gastroenterol，2025，60 from the phase Ⅱ NORSE study［J］. J Clin Oncol，2026，
（2）：235-246 44（8）：676-684
［34］BIBEAU K，FÉLIZ L，LIHOU C F，et al. Progression⁃free ［45］GROCHOT R，JOSHI K，CAMMAROTA A，et al. Safety
survival in patients with cholangiocarcinoma with or with⁃ and activity of fibroblast growth factor receptor inhibitors
out FGF/FGFR alterations：a FIGHT⁃202 post hoc analy⁃ in advanced malignancies：a pooled analysis of early ⁃
sis of prior systemic therapy response［J］. JCO Precis On⁃ phase clinical trials［J］. JCO Precis Oncol，2025，9：
col，2022，6：e2100414 e2400896
［35］KLÜMPER N，COX A，SJÖDAHL G，et al. Pre⁃treatment ［46］MERIC⁃BERNSTAM F，HOLLEBECQUE A，FURUSE J，
metastatic biopsy：a step towards precision oncology for et al. Safety profile and adverse event management for futi⁃
urothelial cancer［J］. Nat Rev Urol，2025，22（5）：256- batinib，an irreversible FGFR1⁃4 inhibitor：pooled safety
267 analysis of 469 patients［J］. Clin Cancer Res，2024，30
［36］GUERCIO B J，SARFATY M，TEO M Y，et al. Clinical （8）：1466-1477
and genomic landscape of FGFR3⁃altered urothelial carci⁃ ［47］CHEN L F. Next⁃generation isoform⁃selective fibroblast
noma and treatment outcomes with erdafitinib：a real ⁃ growth factor receptor inhibitors［J］. Trends Pharmacol
world experience［J］. Clin Cancer Res，2023，29（22）： Sci，2025，46（11）：1091-1104
4586-4595 ［48］SCHÖNHERR H，AYAZ P，TAYLOR A M，et al. Discov⁃
［37］KOSHKIN V S，HENDERSON N，JAMES M，et al. Efficacy ery of lirafugratinib（RLY⁃4008），a highly selective irre⁃
of enfortumab vedotin in advanced urothelial cancer：anal⁃ versible small⁃molecule inhibitor of FGFR2［J］. Proc Natl
ysis from the Urothelial Cancer Network To Investigate Acad Sci U S A，2024，121（6）：e2317756121
Therapeutic Experiences（UNITE）study［J］. Cancer， ［49］DIXIT G，GONZALEZ⁃BOSQUET J，SKURSKI J，et al.
2022，128（6）：1194-1205 FGFR2 mutations promote endometrial cancer progres⁃
［38］LORIOT Y，MATSUBARA N，PARK S H，et al. Erdafi⁃ sion thro⁃ugh dual engagement of EGFR and Notch signal⁃
tinib or chemotherapy in advanced or metastatic urotheli⁃ ling pathways［J］. Clin Transl Med，2023，13（5）：e1223
al carcinoma［J］. N Engl J Med，2023，389（21）：1961- ［50］WANG Y Z，ZHANG Y H，LIU J X，et al. Discovery of
1971 pyrrolopyrazine carboxamide derivatives as potent and se⁃
［39］GNAGNI L，RUSCITO I，ZIZZARI I G，et al. Precision on⁃ lective FGFR2/3 inhibitors that overcome mutant resis⁃